Sugi Predict

Sugi Predict / Compounds / SCHEMBL4371508

SCHEMBL4371508

SCHEMBL4371508

CC(C)(C)NS(=O)(=O)c1cc2cc(c1)Nc1nc(ncc1Br)Nc1cccc(c1)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 9/20 0.41
▸ GAK O14976 1/20 0.39
▸ CDK1 P06493 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ EPHA2 P29317 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ JAK2 O60674 11/20 0.38
▸ JAK1 P23458 11/20 0.38
▸ JAK3 P52333 11/20 0.38
▸ TYK2 P29597 10/20 0.38
▸ PTK2 Q05397 1/20 0.37
▸ PTK2B Q14289 1/20 0.37
▸ STK4 Q13043 1/20 0.35
▸ STK3 Q13188 1/20 0.35
▸ STK26 Q9P289 1/20 0.35
▸ STK24 Q9Y6E0 1/20 0.35
▸ SIRT2 Q8IXJ6 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4365168 0.93 ALK (0.37) ALKGAKCDK1CDK2EPHA2
SCHEMBL4357347 0.89 ALK (0.54) ALKJAK2JAK1JAK3TYK2
SCHEMBL4356260 0.85 GAK (0.43) ALKGAKCDK1CDK2EPHA2
Trifluoroacetic Acid SCHEMBL4352721 0.83 ALK (0.48) ALKJAK2JAK1JAK3TYK2
SCHEMBL4370143 0.81 GAK (0.53) ALKGAKCDK1CDK2EPHA2
Trifluoroacetic Acid SCHEMBL4354423 0.80 GAK (0.38) ALKGAKCDK1CDK2EPHA2
Trifluoroacetic Acid SCHEMBL1074977 0.74 GAK (0.45) ALKGAKCDK1CDK2EPHA2
SCHEMBL4354832 0.70 ALK (0.55) ALKJAK2JAK1JAK3TYK2
SCHEMBL4360745 0.68 ALK (0.52) ALKJAK2JAK1JAK3TYK2
SCHEMBL4359366 0.67 ALK (0.71) ALKJAK2JAK1JAK3TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885GAK 220/4885CDK1 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.